



Literature Monitoring
Literature screening in pharmacovigilance is a critical process that involves searching, retrieving, and evaluating information from various sources to identify potential safety concerns with a drug or medical device. It is a systematic and ongoing process of searching, reviewing, and analyzing published literature and other sources of information for potential adverse drug reactions, new safety concerns, and other relevant pharmacovigilance information. This information is used to identify potential signals of harm and support drug safety decision-making.
Literature monitoring is an important component of pharmacovigilance, as it helps ensure that the latest safety information is incorporated into the benefit-risk assessment of marketed drugs.
We deliver Literature Monitoring Services leveraging our TOTALVigilance framework that is a cost-effective, flexible, and scalable solution designed to reduce manual effort through digitalization, automation, and real-time oversight. It combines expert knowledge, lean processes, and modern technology to deliver high-quality, compliant services. With adaptable service models and seamless integration into your existing systems and workflows, TOTALVigilance enhances operational efficiency, enables proactive oversight, and maximizes return on investment.
With over 15+ years experience, Our highly specialized PV team can help marketing authorization holders to conduct medical literature surveillance at least weekly according to the GVP module VI and based on the required frequency as described by the local regulatory authorities, both for globally indexed literature databases and locally (non-indexed) literature journals.
Digital & Automated Literature Monitoring Services with Realtime & Pro-active Oversight
- Perform comprehensive literature search across medical publications, scientific journals, and biomedical databases (Medline, PubMed, Embase, etc.)
- Develop and implement robust search strategies after completing sensitivity testing to ensure that search criteria are robust and accurate for each product
- Using our proprietary Compier Literature Screening AI application, we can complete rapid article search, extract information from abstracts and retain historical records
- We have a well-established deduplication system to avoid missing relevant references or creating duplicate ISCRs inadvertently
- Our PV experts can conduct literature searches and evaluate the results for literature per regional requirements (Global and Local).
- We always strive towards meeting timelines and avoiding delays in communicating and reporting to regulatory bodies.

TOTALVigilance Services
End-to-End Pharmacovigilance Solutions
Pharmacovigilance Technology Solutions
Leverage our 15+ years of comprehensive experience and our portfolio of System Integration (SI) and Managed Cloud Services to enhance regulatory compliance in pharmacovigilance.
Pharmacovigilance Operations Oversight & Agentic AI Solutions
Manual oversight is often inefficient and error-prone, leading to compliance risks. As a result, there is a growing need for a digital, automated PV oversight framework to enhance efficiency, data quality, and real-time regulatory compliance
Operations Oversight & Agentic AI Platform – Compier PV Ops
Unique SaaS platform that co-exist with drug safety databases enable companies to proactively manage and automate global Pharmacovigilance compliance operations.
Integrated & Automated Functional Services
Life sciences organizations need a modern delivery framework that is purpose-built for agility, scalability, and compliance to efficiently address all of the regulatory obligations towards Pharmacovigilance.
TOTALVigilance - Functional Services
Simplify End-to-End Pharmacovigilance Compliance Obligations by combining People, Process, Technology, Automation & Quality.
Latest Relevant Case Studies

December 29, 2022
Establishing an Integrated Global Drug Safety and Signal Management Cloud Solution

December 29, 2022
Argus Safety Cloud Implementation and Validation on Oracle Cloud for HUGEL Pharma

December 29, 2022
Serious Adverse Event (SAE) Management, Review and Reporting to DCGI during the COVID 19 Pandemic for an Ophthalmology Clinical Study
Latest Relevant Insights

August 30, 2021
Literature Screening – Process overview, challenges en-route and the scope for automation